Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MWfLbY5ie2ViQYPzZZk> NGC4S2YzPCCq NEf4ZYZKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= MlPqNlQ3PDFzMEO=
COLO205 NIO5TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj1OmE4OiCq M{P1dmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO MYGyOFY1OTFyMx?=
U937 M2DBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHGW2hSPzJiaB?= Mn:5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> Mmf0NlQ3PDFzMEO=
MOLM13 NX31RpJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3jUopGPzJiaB?= NHLPToZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{Bp[XKkb4LpcochTkyWMzDJWGQhdXW2YX70JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO NITpdoIzPDZ2MUGwNy=>
MOLM13 M{H1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnCNJU4OiCq NYPJSFhYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB{d3KjZnXubYIuemW|aYP0ZY51KGi3bXHuJG1QVE1zMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNwenCxcnH0bY9vKG:oIGuzTH11cHmvaXTpcoUhcW62bzDEUmEhf2m2aDDJR|UxKG:oIECuNFk3KM7:TR?= M1Ty[lI1PjRzMUCz
MDA-MB-435 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nPR|I1KGh? NYDrOIk4UUN3ME2wMlE3KM7:TR?= Mm\0NVU5ODF6M{G=
K562 Mnq5R5l1d3SxeHnjJGF{e2G7 NE\pWFQ6PiCq MkP2SG1UVw>? NWLabFB[UUN3ME2yJO69VQ>? MkjBNlQ1OTd3Nk[=
DU145 MX7DfZRwfG:6aXOgRZN{[Xl? NIT4cog6PiCq M{DaOmROW09? M1r2NWlEPTB;Nz61JO69VQ>? M3j6[|I1PDF5NU[2
MDA-MB-231 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[yNUDPxE1? NWjYUWtuOjRiaB?= NWnoUpNLTE2VTx?= NFm5blBE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> NXrIbm1sOjR2MUe1OlY>
MCF7 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LPfVEh|ryP M3LVT|I1KGh? MYXEUXNQ NFWyT|lE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> NVjYV4ZkOjR2MUe1OlY>
MCF7 M4Hyd2tqdmG|ZTDBd5NigQ>? MoHjOUDPxE1? MnzONlQhcA>? MVPEUXNQ NXP6flYyUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> NVPBfYxNOjR2MUe1OlY>
MDA-MB-231 NEHkeJdMcW6jc3WgRZN{[Xl? MVG1JO69VQ>? NYriU3lyOjRiaB?= MkDVSG1UVw>? NGPnZmdKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NITDV4kzPDRzN{W2Oi=>
MDA-MB-231 M3HXPGZ2dmO2aX;uJGF{e2G7 M3[xU|EuOTBizszN NVHZcJJbOjRiaB?= MYTEUXNQ MnG5[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen M2jKNlI1PDF5NU[2
MCF7 NWDlfm1DTnWwY4Tpc44hSXO|YYm= NUDFOIVDOS1zMDFOwG0> NFXvT2UzPCCq M1;zbGROW09? MWHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? NFvG[pYzPDRzN{W2Oi=>
MDA-MB-231 NI[3N3FHfW6ldHnvckBCe3OjeR?= NHXwOpAxNjVvMTFOwG0> NYC3NlVWPDhiaB?= NHPWOFVFVVOR MmqxbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> MXyyOFQyPzV4Nh?=
MCF7 MXXGeY5kfGmxbjDBd5NigQ>? NH3Yd3MxNjVvMTFOwG0> M3r3OFQ5KGh? M4C1d2ROW09? NGXu[opp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? M4rud|I1PDF5NU[2
697 M4PjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnuTWM2OD1zNEiuN|ghdk1? MWXTRW5ITVJ?
P12-ICHIKAWA NUDiUpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTl4LkC0JI5O MmjnV2FPT0WU
NB69 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XONGlEPTB;MU[xMlghdk1? M4ryUXNCVkeHUh?=
EoL-1 NFntPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnnbHBKSzVyPUG4O{4zPiCwTR?= NX:ybYt4W0GQR1XS
BHT-101 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLNTohoUUN3ME2xPVgvOjVibl2= NH;XS|FUSU6JRWK=
SK-NEP-1 M3jq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfwTWM2OD1{MkCuNFIhdk1? NXnidWtNW0GQR1XS
MHH-NB-11 M{j4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXXU4VKSzVyPUKyNE4yQSCwTR?= NFPQd3RUSU6JRWK=
AsPC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ3Mj61N{BvVQ>? NXzNTHlSW0GQR1XS
ES1 M4q2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jrPWlEPTB;MkW2MlI2KG6P MX3TRW5ITVJ?
LAMA-84 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXTWM2OD1{NUiuNVkhdk1? Mlm1V2FPT0WU
MOLT-16 M1;iRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn23TWM2OD1{NUiuOFkhdk1? MlnzV2FPT0WU
ES7 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TCWGlEPTB;MkezMlA6KG6P MmX3V2FPT0WU
KY821 NEjmXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixOYxjUUN3ME2zNVQvOSCwTR?= MonTV2FPT0WU
RT-112 NH;Ze41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN{MT6wOUBvVQ>? NGLTV29USU6JRWK=
HL-60 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojNTWM2OD1|NECuOlYhdk1? NFfRR2NUSU6JRWK=
MOLT-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\PSYRsUUN3ME2zOFUvOTNibl2= NU[yXGoyW0GQR1XS
KARPAS-45 M4r4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvJZnhuUUN3ME2zO|YvOTZibl2= MVjTRW5ITVJ?
SK-N-AS NVjnPWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTN6Nz64N{BvVQ>? Mm\MV2FPT0WU
CTB-1 NYXpUWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGxeJVKSzVyPUSwOU4xOiCwTR?= NEjzUZJUSU6JRWK=
NKM-1 NXvCU4xGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKxcmhKSzVyPUSxNU45QSCwTR?= NVq4W4R4W0GQR1XS
HTC-C3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXjO|NKSzVyPUSzNk46PSCwTR?= M1TnS3NCVkeHUh?=
BE-13 NEjIdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS5dIF6UUN3ME20OFQvOjdibl2= M370UnNCVkeHUh?=
KOSC-2 NWXpU4tiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fkemlEPTB;NE[2Mlkhdk1? NFLoVmpUSU6JRWK=
NB14 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHscFk5UUN3ME20PFMvPThibl2= NUfUOXIxW0GQR1XS
CAL-27 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTR7ND61PUBvVQ>? NWPjWI5ZW0GQR1XS
H9 M3PmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHEeXh{UUN3ME20PVUvPDNibl2= NXnYVWtRW0GQR1XS
RS4-11 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLITWM2OD13MESuO|Mhdk1? M2PqcXNCVkeHUh?=
PA-1 M1W3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVyOT64OkBvVQ>? NXjJOHV2W0GQR1XS
MV-4-11 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTVzMz64OUBvVQ>? Ml25V2FPT0WU
OS-RC-2 NHLxXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTPSHFKSzVyPUWyNU43OiCwTR?= NW[yOXliW0GQR1XS
RPMI-8226 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnxRpVKSzVyPUWyOk45PiCwTR?= NIjkWHhUSU6JRWK=
HGC-27 M4rTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf4bI93UUN3ME21OlQvQTlibl2= M3rYXHNCVkeHUh?=
CHP-212 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPHO5JKSzVyPUW5N{42QSCwTR?= NGjMc4lUSU6JRWK=
NB10 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjFSGRKSzVyPUW5PU4yQCCwTR?= NVvuUodzW0GQR1XS
HH MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HNSWlEPTB;NUm5MlQ{KG6P Mn\VV2FPT0WU
EW-16 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPGdXQxUUN3ME22NFMvPTJibl2= M3Hu[3NCVkeHUh?=
ES8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLQVYpDUUN3ME22NFUvOjFibl2= M4n5UXNCVkeHUh?=
HAL-01 NYPXWW9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzqTWM2OD14MEWuOlchdk1? MmWxV2FPT0WU
A204 NF[4b4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;aTWM2OD14M{OuPVEhdk1? NUPzUWlWW0GQR1XS
MHH-PREB-1 M1jkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XvUGlEPTB;NkO2Mlk6KG6P M2foS3NCVkeHUh?=
EM-2 NHyzcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTsSGc2UUN3ME22OVAvPjRibl2= NUP3e25tW0GQR1XS
BV-173 M3rhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTZ3Mj60PEBvVQ>? MUTTRW5ITVJ?
ONS-76 NXGyUmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZ5Nz64NkBvVQ>? NY[1b5h1W0GQR1XS
KM-H2 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XnO2lEPTB;Nkm1MlU1KG6P MnjlV2FPT0WU
D-263MG NYn4[5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m1[WlEPTB;N{G3MlEzKG6P M4DLSHNCVkeHUh?=
ES3 NVXYb3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\aTWM2OD15MkiuPVMhdk1? NG[wUpFUSU6JRWK=
VA-ES-BJ NEPBbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfiTJZ2UUN3ME23N|IvOjdibl2= NWDZ[ZlXW0GQR1XS
NBsusSR M{juWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L0TWlEPTB;N{SyMlk6KG6P MkHUV2FPT0WU
NCI-H520 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\uZ2lEPTB;N{S2MlUzKG6P M{nnT3NCVkeHUh?=
ES5 NH7WWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\jdmZiUUN3ME23OVIvQCCwTR?= NF\tSG5USU6JRWK=
T-24 NVnXV3k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS2TWM2OD15N{iuO|Ehdk1? M1fQOnNCVkeHUh?=
SW962 NXnWT2hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e3NGlEPTB;OEC4MlY{KG6P NEHaOJlUSU6JRWK=
EW-3 M{fndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRThyOD63OkBvVQ>? MXzTRW5ITVJ?
RXF393 NV\XeJA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXrSHhqUUN3ME24NVIvPzlibl2= NETZZWdUSU6JRWK=
U251 NHviVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrVdYtWUUN3ME24NVMvQDhibl2= MXjTRW5ITVJ?
CAMA-1 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTh|Mz65OEBvVQ>? MV\TRW5ITVJ?
JVM-3 NIjLe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nGSWlEPTB;OEWxMlc5KG6P MYHTRW5ITVJ?
COLO-800 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjoRodKSzVyPUi5O{44QCCwTR?= M3vrOnNCVkeHUh?=
OVCAR-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7D[YFKSzVyPUmwNE4yKG6P NYCxUHlDW0GQR1XS
LB1047-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPFS5ZKSzVyPUmyO{42PiCwTR?= NETrSZFUSU6JRWK=
SW954 NV32OYJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDXTWM2OD17MkmuOFEhdk1? Mle0V2FPT0WU
J-RT3-T3-5 M{XXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHoWphQUUN3ME25N|YvODZibl2= M2LDeHNCVkeHUh?=
Mewo MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTl|Nj62JI5O M2rqSHNCVkeHUh?=
NCI-H1770 M{T0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnINnN{UUN3ME25OFAvPTVibl2= MXrTRW5ITVJ?
HO-1-N-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnJTWM2OD17NkKuPFEhdk1? NEHoc2VUSU6JRWK=
HSC-3 NWTteJJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHvUZV2UUN3ME25OlYvPDhibl2= MXrTRW5ITVJ?
TYK-nu MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPvUZpKSzVyPUm5PE4zPSCwTR?= NIDUfYxUSU6JRWK=
KYSE-150 NX7Sd2x4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwMECwO|Yh|ryP NWTQUFJRW0GQR1XS
SN12C MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwMEC4O|Uh|ryP NXnJTGxxW0GQR1XS
MOLT-13 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\ROZJKSzVyPUGuNFE1OjFizszN MnHaV2FPT0WU
TE-11 M3e1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwMES4NVIh|ryP MYPTRW5ITVJ?
DB MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD5d|J2UUN3ME2xMlA4Ojd|IN88US=> MV3TRW5ITVJ?
CAL-39 NHzyNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDzfWZKSzVyPUGuNFc2OjJizszN Mn6wV2FPT0WU
A3-KAW M1vBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;5ZWhCUUN3ME2xMlA5PDB6IN88US=> MmTTV2FPT0WU
CHP-134 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTsSplKSzVyPUGuNVE5ODdizszN NHrjcFlUSU6JRWK=
TGW NUH1UIptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULlRXFWUUN3ME2xMlEzOzl3IN88US=> NYqw[JB7W0GQR1XS
QIMR-WIL NVrTXmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPoSHdpUUN3ME2xMlE{OTN2IN88US=> M1nwVXNCVkeHUh?=
NCI-SNU-1 M3rPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFwMU[zOVQh|ryP MXTTRW5ITVJ?
CGTH-W-1 M1nue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMUexPFYh|ryP Ml3ZV2FPT0WU
MHH-ES-1 M3;ZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFwMUe5PFYh|ryP MVHTRW5ITVJ?
LB2241-RCC NFT3c5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXWRYJCUUN3ME2xMlE5PjJizszN MnKxV2FPT0WU
ML-2 NXzQXYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwMkC3N|Qh|ryP NUHXOoY4W0GQR1XS
COR-L23 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOzTWM2OD1zLkKyPVM{KM7:TR?= NYPJc3BpW0GQR1XS
BFTC-905 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzid5BKSzVyPUGuNlQzPjdizszN MYDTRW5ITVJ?
Hs-578-T NV\XdohrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmyTWM2OD1zLkK1PFE4KM7:TR?= MkTaV2FPT0WU
KG-1 NUnGcHJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLFTWM2OD1zLkK2Olg3KM7:TR?= NX7QeVByW0GQR1XS
HEL M{fXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ji[WlEPTB;MT6yPVM{QCEQvF2= Ml;WV2FPT0WU
A549 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\aV25KSzVyPUGuNlk{QTlizszN M1nqPXNCVkeHUh?=
COLO-741 M1mxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fhOGlEPTB;MT6zNlA5QSEQvF2= MYXTRW5ITVJ?
PC-3 NGLTfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TXZmlEPTB;MT6zOVIzOSEQvF2= M3zFTHNCVkeHUh?=
HOS MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm3W3VlUUN3ME2xMlM2Ojl4IN88US=> MWrTRW5ITVJ?
HT-1080 NUjNemhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwM{e1NVkh|ryP NX\pV|RMW0GQR1XS
TE-8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rTZWlEPTB;MT60NVc4PCEQvF2= M1LHUHNCVkeHUh?=
BHY NWLGT3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjTIxKSzVyPUGuOFY6OjNizszN MoDMV2FPT0WU
BB65-RCC NUDrVlNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwNUC1Nlgh|ryP MoK3V2FPT0WU
HN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fmWGlEPTB;MT61OFA4OSEQvF2= Ml;xV2FPT0WU
NCI-H441 NHXOfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwNUS5NFch|ryP NVvtWIw5W0GQR1XS
RPMI-8866 NE\rXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:zTGlEPTB;MT61PFUxPyEQvF2= Ml2xV2FPT0WU
CAL-62 NF\YVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW5fo45UUN3ME2xMlYxQDZ{IN88US=> NU\mbIp{W0GQR1XS
MG-63 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHCXmhuUUN3ME2xMlYyQDF|IN88US=> MkTXV2FPT0WU
SK-LU-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzsTWM2OD1zLk[yNVUzKM7:TR?= NF;BRppUSU6JRWK=
BCPAP NGjiOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjZNlJKSzVyPUGuOlY1PTdizszN NF\4Ro5USU6JRWK=
22RV1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17We2lEPTB;MT62O|g1OyEQvF2= M3zFeXNCVkeHUh?=
T47D M3\ET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwNkiwOlEh|ryP MoHmV2FPT0WU
MSTO-211H NE\IeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjJ[JBKSzVyPUGuOlk3ODNizszN NWnTdGU1W0GQR1XS
DEL MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf0TWM2OD1zLkewNlc{KM7:TR?= NGC4bGhUSU6JRWK=
H4 NEnqUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF33XJhKSzVyPUGuO|MzOTJizszN MWXTRW5ITVJ?
CAL-51 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwN{S4OVUh|ryP NIr2WIlUSU6JRWK=
ABC-1 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S2XGlEPTB;MT63PFU5OiEQvF2= MVLTRW5ITVJ?
MZ2-MEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u0OmlEPTB;MT63PVU1OiEQvF2= MoDyV2FPT0WU
YKG-1 M1n5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjWOFlKSzVyPUGuPFExPjFizszN NUnxbHBRW0GQR1XS
KM12 NYDVTVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHaTWM2OD1zLkixOlAzKM7:TR?= MknpV2FPT0WU
L-363 NUHOOZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zuSmlEPTB;MT64O|QyOiEQvF2= NF;5cXdUSU6JRWK=
KU812 NFi5XYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj6RmF{UUN3ME2xMlg6Ojh{IN88US=> NX7vVGZXW0GQR1XS
LOXIMVI NI\OT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLFTWM2OD1zLkmxNlI5KM7:TR?= MkXLV2FPT0WU
G-401 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TuVGlEPTB;MT65NlQzQCEQvF2= MVnTRW5ITVJ?
SW780 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHpTWM2OD1zLkm2NlQ3KM7:TR?= M4HRWXNCVkeHUh?=
SW872 NEj5WotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwOUizN{DPxE1? Mlr1V2FPT0WU
NB7 M3j5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uxSGlEPTB;MT65PVMzOyEQvF2= NH20dmlUSU6JRWK=
T98G MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPETWM2OD1{LkCwOlY3KM7:TR?= NVy5V29nW0GQR1XS
SW1710 M1;5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuxd2pGUUN3ME2yMlA3QTR3IN88US=> M2\qdnNCVkeHUh?=
NCI-H1573 M1zaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K2TWlEPTB;Mj6wO|I6QCEQvF2= M4jmWXNCVkeHUh?=
KE-37 NUXyVFN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJwMEi5OVEh|ryP MnS1V2FPT0WU
786-0 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LjRmlEPTB;Mj6xOVQ{QSEQvF2= MYjTRW5ITVJ?
SAS NYrUb3NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvVRVRKSzVyPUKuNlA{PzRizszN MYDTRW5ITVJ?
CAL-54 NH25OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXwVohKSzVyPUKuNlA1OTNizszN MWLTRW5ITVJ?
SF268 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTOTWM2OD1{LkKzNVIzKM7:TR?= Ml;WV2FPT0WU
SW620 NHTEe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17G[2lEPTB;Mj6yOlE3QSEQvF2= NXzXfVg2W0GQR1XS
MN-60 NH6yN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3rNIpKSzVyPUKuN|ExPiEQvF2= NIC5Z3NUSU6JRWK=
EFO-27 NVrnbnRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLmTWM2OD1{LkOyNFU5KM7:TR?= MmLsV2FPT0WU
NCI-H747 NHLRUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PocmlEPTB;Mj6zNlE6QSEQvF2= M2Hyc3NCVkeHUh?=
HCC2218 M13wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvWSZBiUUN3ME2yMlM2Ozd2IN88US=> MXrTRW5ITVJ?
MIA-PaCa-2 NXLacHEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwM{[0N|ch|ryP MU\TRW5ITVJ?
SJSA-1 NF\rSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DoVmlEPTB;Mj6zO|c6PiEQvF2= NYn3WVRRW0GQR1XS
RKO M1PZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vWUWlEPTB;Mj6zPFQ6PiEQvF2= M1T6eHNCVkeHUh?=
NB6 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v6TmlEPTB;Mj60NFM4PCEQvF2= MWXTRW5ITVJ?
ES4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX6UZVKSzVyPUKuOFU1OjJizszN M3rUfHNCVkeHUh?=
EGI-1 NWjO[opTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwNE[4PFMh|ryP NFzR[lFUSU6JRWK=
CTV-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jk[mlEPTB;Mj61Nlc4OyEQvF2= Mn2yV2FPT0WU
NCI-H1355 M3XvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXoTWM2OD1{LkW1PVUyKM7:TR?= NF\2WZZUSU6JRWK=
GT3TKB MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XncmlEPTB;Mj61PVE6QSEQvF2= MWLTRW5ITVJ?
SK-HEP-1 NWXXXGNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTMWo17UUN3ME2yMlU6OjZ4IN88US=> MWfTRW5ITVJ?
GAMG MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq3UWZmUUN3ME2yMlU6Ozl2IN88US=> NG\4SmJUSU6JRWK=
SK-MES-1 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr0XmVxUUN3ME2yMlYyQDB|IN88US=> MVLTRW5ITVJ?
RO82-W-1 NX;Sd|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XiOGlEPTB;Mj62NlA2PyEQvF2= NUPvPGxzW0GQR1XS
ECC10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\QNlFbUUN3ME2yMlcxOjB4IN88US=> M4X1O3NCVkeHUh?=
MCF7 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDS[pNKSzVyPUKuO|E1PjRizszN NGrYUo5USU6JRWK=
D-283MED MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrrOnl2UUN3ME2yMlczPDNizszN MVTTRW5ITVJ?
RPMI-7951 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDwZml5UUN3ME2yMlc2Pjl2IN88US=> M{fCW3NCVkeHUh?=
Ramos-2G6-4C10 NFi2cVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\ITWM2OD1{Lke3NFk6KM7:TR?= M3S5UnNCVkeHUh?=
KGN NUO2S3lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnTb3pbUUN3ME2yMlgyQDh2IN88US=> NWe3RndMW0GQR1XS
NUGC-3 NE[5[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX1TWM2OD1{LkiyOVA2KM7:TR?= NXTtWIR2W0GQR1XS
NCI-H292 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwOEWwOVMh|ryP MYrTRW5ITVJ?
Becker NWXqfXRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLLZ3NKSzVyPUKuPVU5OzJizszN Mor6V2FPT0WU
NCI-H1299 NID5PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrNTWM2OD1|LkC1NlY{KM7:TR?= M365fnNCVkeHUh?=
ETK-1 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;mO|BKSzVyPUOuNFU1OyEQvF2= MkXXV2FPT0WU
TK10 MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v2VmlEPTB;Mz6yNFE3PSEQvF2= NHvBTFZUSU6JRWK=
VMRC-RCZ M1TBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwM{[0PFgh|ryP MmjDV2FPT0WU
YH-13 M1XMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTXdWRKSzVyPUOuOFQxPzlizszN NHvoUWFUSU6JRWK=
DU-145 NGLuXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwNE[yOlkh|ryP MYXTRW5ITVJ?
SW1088 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULUUFI{UUN3ME2zMlQ4PDdizszN M{LQfHNCVkeHUh?=
HOP-92 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rLUGlEPTB;Mz61NFM1OiEQvF2= NFv3cHVUSU6JRWK=
KP-N-YS M1nKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\TUnFwUUN3ME2zMlYzOTN7IN88US=> Mo[wV2FPT0WU
NCI-H460 NVLlWVZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36wcmlEPTB;Mz62Olc{KM7:TR?= NXricG92W0GQR1XS
U-2-OS NETwVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LURmlEPTB;Mz63NlU{PSEQvF2= NImwenZUSU6JRWK=
A101D NF7EbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNwN{[5N|Yh|ryP MUHTRW5ITVJ?
MDA-MB-231 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjpRYxKSzVyPUOuPFE6PTFizszN NWLOXXhiW0GQR1XS
IST-MES1 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi1WIg{UUN3ME2zMlg{OiEQvF2= M{S2UHNCVkeHUh?=
COR-L105 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrxTWM2OD12LkCxPEDPxE1? NFX6XHBUSU6JRWK=
NCI-H1437 M3ThXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTRwMEKzNFIh|ryP NITjcJVUSU6JRWK=
CAL-85-1 M36zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m2N2lEPTB;ND6wNlQ3OSEQvF2= NW\WZmgyW0GQR1XS
MZ1-PC NYDUc3E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\rUWlEPTB;ND6xPFU2PiEQvF2= NV3i[JpKW0GQR1XS
VM-CUB-1 NIfIZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO3TWM2OD12LkOxNlg1KM7:TR?= NIr5NHZUSU6JRWK=
CHL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILUVldKSzVyPUSuN|IyPjlizszN NH7PNmlUSU6JRWK=
MDA-MB-361 NX7hSW81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G0dGlEPTB;ND6zN|E2OyEQvF2= NWn1bWdJW0GQR1XS
NCI-H661 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;QUXd2UUN3ME20MlUxODl{IN88US=> MWDTRW5ITVJ?
EW-11 NFTWTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDiN2NGUUN3ME20MlUzOjNzIN88US=> NHrWPINUSU6JRWK=
BEN NYTVVZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnCSlBKSzVyPUSuOVI5OTVizszN M3S3fXNCVkeHUh?=
BFTC-909 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwNU[yO|Uh|ryP NHjHPHJUSU6JRWK=
NCI-H2087 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonBTWM2OD12LkW4NVY1KM7:TR?= MWTTRW5ITVJ?
RVH-421 NHHnbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Ln[GlEPTB;ND62OlY6KM7:TR?= Ml\IV2FPT0WU
P30-OHK MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r5PGlEPTB;ND62PFAxQCEQvF2= M3O3dnNCVkeHUh?=
NCI-H28 M36zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HnTGlEPTB;ND64NVY3OSEQvF2= MljWV2FPT0WU
ES6 M1PS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHabGp5UUN3ME20Mlg{ODF4IN88US=> MmjNV2FPT0WU
769-P NXraU|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC1WIhjUUN3ME20Mlg2QTJ4IN88US=> NHzT[3RUSU6JRWK=
OE33 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v4WGlEPTB;ND64PFE3OSEQvF2= NYDLe2p7W0GQR1XS
SW982 M2iyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTRwOUWwOlEh|ryP NYPXfWl1W0GQR1XS
A388 M3HhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjMc2FKSzVyPUWuNFI6QDNizszN MmfMV2FPT0WU
TI-73 NXLaWm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[5TWM2OD13LkC2NVk1KM7:TR?= MlHBV2FPT0WU
HCT-116 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe5TGhoUUN3ME21MlA6QDh7IN88US=> MnzKV2FPT0WU
HuP-T3 M1L4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXSTWM2OD13LkG4O|A6KM7:TR?= MX3TRW5ITVJ?
G-402 NHXRVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHJTWM2OD13LkG5OFE3KM7:TR?= NGDpOFNUSU6JRWK=
NCI-H1792 NFO1b|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TBbmlEPTB;NT6yOFYzOiEQvF2= MWfTRW5ITVJ?
NCI-H209 NFPTblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXsTWM2OD13LkK1PVQzKM7:TR?= M3SxcnNCVkeHUh?=
NCI-H1650 M{mx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHLTWM2OD13LkOwOlM1KM7:TR?= MX;TRW5ITVJ?
LCLC-97TM1 M3u5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj1TYE{UUN3ME21MlMyQDB6IN88US=> NITOSG1USU6JRWK=
S-117 M4TaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrZTWM2OD13LkO2PVc3KM7:TR?= NWnhbYZ3W0GQR1XS
GI-ME-N NWHobpNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\RN|JKSzVyPUWuN|k3QDFizszN MX3TRW5ITVJ?
NCI-H2122 NX;LWYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTVwNEmzPVch|ryP Mo\JV2FPT0WU
NCI-H1793 NY\2cXN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLVcllKSzVyPUWuOlc2QTNizszN Mk\OV2FPT0WU
C2BBe1 NGT2TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTVwN{CwPFgh|ryP M1\FbXNCVkeHUh?=
TE-12 NVq0S3A1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7iOnRsUUN3ME21MlgxPTV4IN88US=> MoP5V2FPT0WU
LCLC-103H MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj2TWM2OD13LkmxO{DPxE1? NXm2U2lOW0GQR1XS
A673 NGfsN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwOUG5N|Ih|ryP M4HZNnNCVkeHUh?=
BB30-HNC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO1VJhTUUN3ME21Mlk5OzZizszN NXLqboZlW0GQR1XS
SF295 M3TZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrWcZoyUUN3ME22MlAxPDJ{IN88US=> MmPZV2FPT0WU
KU-19-19 NYHhW3BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZwMEG3N|Eh|ryP NIqze4VUSU6JRWK=
CFPAC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S2e2lEPTB;Nj6wOFQ1OyEQvF2= NY\Q[WdkW0GQR1XS
LoVo MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfNXGtEUUN3ME22MlA2ODZ|IN88US=> NXKzfm96W0GQR1XS
8505C MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofmTWM2OD14LkC3OVc{KM7:TR?= NHLKZmpUSU6JRWK=
GMS-10 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33DfGlEPTB;Nj6xOVAxOiEQvF2= NH;oVJFUSU6JRWK=
Ca9-22 NVj6WFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;FfFhrUUN3ME22MlE3PzFizszN MmXWV2FPT0WU
DOK MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn6THBKSzVyPU[uNlIxPzJizszN M2DTUHNCVkeHUh?=
FADU NUmydYFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe1TFVCUUN3ME22MlI3ODN7IN88US=> NE\TUoZUSU6JRWK=
BxPC-3 NUj1S2xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF36OG9KSzVyPU[uNlc{OiEQvF2= MV;TRW5ITVJ?
CAL-33 M33tfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XzNWlEPTB;Nj6yPVIxOSEQvF2= NGLkRoVUSU6JRWK=
SHP-77 M{PnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\DbHpTUUN3ME22MlMyPTF{IN88US=> M{fEUHNCVkeHUh?=
LXF-289 NGDlNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfoSpF7UUN3ME22MlM{PDV3IN88US=> NIHDTWhUSU6JRWK=
GB-1 NYfJUJFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnTUJkxUUN3ME22MlM5OiEQvF2= MXnTRW5ITVJ?
KS-1 NYruN212T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZwM{i0OFch|ryP M1joVHNCVkeHUh?=
D-502MG M2jUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvZRXlsUUN3ME22MlQzOzd4IN88US=> MXTTRW5ITVJ?
LAN-6 MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXJTWM2OD14LkWxNFI{KM7:TR?= NILoWlFUSU6JRWK=
H-EMC-SS NGTES2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7CXGlKSzVyPU[uOVYyPDdizszN MXTTRW5ITVJ?
LC-2-ad MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTZwNkCwO|Yh|ryP MWrTRW5ITVJ?
NCI-H1693 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LBRWlEPTB;Nj62NlIyPSEQvF2= NXLFV21sW0GQR1XS
SK-N-FI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPYfIw{UUN3ME22Mlc2ODR2IN88US=> MXrTRW5ITVJ?
D-423MG M1zJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDZTWM2OD14Lke2NVE4KM7:TR?= NXPUOnB5W0GQR1XS
KNS-42 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXzTZhKSzVyPU[uO|gyQTdizszN Mn7iV2FPT0WU
GCT Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorMTWM2OD14LkmzPEDPxE1? M3K2enNCVkeHUh?=
DSH1 M4f6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHhTWM2OD15LkC2N|Mh|ryP MkC4V2FPT0WU
D-247MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\oWnNKSzVyPUeuNFc5QDFizszN MYLTRW5ITVJ?
NCI-SNU-5 NHnZOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTdwMUizO|Eh|ryP MUjTRW5ITVJ?
TE-6 NVnkcpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\vTWM2OD15LkKwOlAyKM7:TR?= M1v5dnNCVkeHUh?=
NOMO-1 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj0eIlKSzVyPUeuNlIyOjdizszN NFrSR2JUSU6JRWK=
NB17 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH2[mNKSzVyPUeuN|A{ODlizszN MULTRW5ITVJ?
EW-22 NX7y[nBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17vN2lEPTB;Nz6zOFM1QCEQvF2= NWTsSpg2W0GQR1XS
EW-13 NGHpd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP3TWM2OD15LkO1NVYzKM7:TR?= NInT[ZdUSU6JRWK=
DOHH-2 M{PHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLnU49DUUN3ME23MlQ1ODJizszN MUjTRW5ITVJ?
TGBC1TKB Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITsVJZKSzVyPUeuOFk5QTlizszN MYDTRW5ITVJ?
GR-ST MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG5XVhsUUN3ME23MlUzPTl2IN88US=> MXvTRW5ITVJ?
KYSE-520 NGDhbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTdwNUW1NVUh|ryP MnrvV2FPT0WU
CAPAN-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTdwNUm1NUDPxE1? MYPTRW5ITVJ?
HCE-4 M3;RTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXMTWM2OD15Lk[yNlc6KM7:TR?= MVzTRW5ITVJ?
MLMA MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6zfXd6UUN3ME23MlYzQTV5IN88US=> M3LsSnNCVkeHUh?=
HT-144 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlraTWM2OD15Lk[1N|Y5KM7:TR?= Mme1V2FPT0WU
KYSE-180 M4HiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XqXGlEPTB;Nz63NVE3QSEQvF2= M2f1SXNCVkeHUh?=
TE-5 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLKXWZKSzVyPUeuPVU6PzFizszN NWP2TFVmW0GQR1XS
IGROV-1 NGXvZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTaTWM2OD15Lkm4OVUyKM7:TR?= NEK4[4NUSU6JRWK=
NCI-H1581 NY\4cIQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yxSGlEPTB;OD6wNVIh|ryP MkTiV2FPT0WU
SW1990 NUW0OpZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqxTWM2OD16LkC0OlU6KM7:TR?= Mn\VV2FPT0WU
EFM-19 M{jLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXkTWM2OD16LkC4OVQ2KM7:TR?= NFzVWmRUSU6JRWK=
OGR-1 M{jQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRThwNEOwNlMh|ryP NYDkXJJPW0GQR1XS
U-118-MG NE\hb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz2bnZxUUN3ME24MlQ{PDZ|IN88US=> M3rxeXNCVkeHUh?=
SK-OV-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\oT2dKSzVyPUiuOFY4PjVizszN NIr4VHJUSU6JRWK=
KNS-62 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;XXmlEPTB;OD61NVc3OSEQvF2= MULTRW5ITVJ?
GOTO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTTTWM2OD16LkW3OlM2KM7:TR?= MYTTRW5ITVJ?
8305C M3;sRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rOcmlEPTB;OD63NFQ5PCEQvF2= MXHTRW5ITVJ?
RPMI-2650 NYHqc4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwN{G5OVUh|ryP NIro[YlUSU6JRWK=
NEC8 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRThwN{SzNFch|ryP MUDTRW5ITVJ?
KYSE-450 NGHF[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrEWG5KSzVyPUiuPFY2PDhizszN NWi3ZnR[W0GQR1XS
RMG-I NWHHT295T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTlwMUSwOVgh|ryP MX7TRW5ITVJ?
CAKI-1 M{jGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPZOFJTUUN3ME25MlMyQTd7IN88US=> M4DFfHNCVkeHUh?=
KYSE-510 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm4[|NKSzVyPUmuN|U4PzhizszN M{TWTnNCVkeHUh?=
A4-Fuk NGDjT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LBbmlEPTB;OT6zOlcxOSEQvF2= MWfTRW5ITVJ?
AN3-CA NWq3U|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPGZlVKSzVyPUmuOFU1PDRizszN MmfBV2FPT0WU
SK-N-DZ M2f6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPKTWM2OD17LkeyPFQ6KM7:TR?= Ml;qV2FPT0WU
HSC-2 M1PmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTLSGJJUUN3ME25Mlc3PjJ7IN88US=> NGDmZ29USU6JRWK=
EW-1 NIDNXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\2TWM2OD17Lke5N|Y6KM7:TR?= MWLTRW5ITVJ?
D-566MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLUGlEPTB;OT64N|Y3PCEQvF2= NH7nT3RUSU6JRWK=
COLO-792 NI[3dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LndWlEPTB;OT65PFc1PiEQvF2= MYTTRW5ITVJ?
TE-10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7icIlKSzVyPUGwMlA{QTZizszN MY\TRW5ITVJ?
NCI-H650 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjpUpNKSzVyPUGwMlQzQDZizszN MUTTRW5ITVJ?
U-266 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HOUWlEPTB;MUCuOFU2KM7:TR?= NHnYOYJUSU6JRWK=
Detroit562 M2fhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nqemlEPTB;MUGuNFUyPSEQvF2= MnmwV2FPT0WU
NH-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[xS2VKSzVyPUGxMlE1PDZizszN NV\wUYhNW0GQR1XS
CO-314 M4X6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFzLkK4OFIh|ryP MXLTRW5ITVJ?
IST-MEL1 NIPHOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnKWIZuUUN3ME2xNU42OzJ|IN88US=> NYfoS2t6W0GQR1XS
KNS-81-FD NUDESFVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3tTWM2OD1zMT61OVI4KM7:TR?= NXy3dpZ5W0GQR1XS
SW1463 NFrSNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFzLkW5PFkh|ryP Mn3PV2FPT0WU
NCI-H23 M1i5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjH[nl2UUN3ME2xNU43PTV{IN88US=> NXvaU|hOW0GQR1XS
SK-MEL-2 NGHBTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjGOYZNUUN3ME2xNU44OTl5IN88US=> NFHESYFUSU6JRWK=
NB13 M4LOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLWTWM2OD1zMj6xOFk2KM7:TR?= NUPIZVA{W0GQR1XS
Daoy M{XoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TWWGlEPTB;MUKuNlg2PiEQvF2= M1nvdnNCVkeHUh?=
NCI-H1623 M4Ptcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHCTWM2OD1zMj6zPFAyKM7:TR?= M3raeXNCVkeHUh?=
NMC-G1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPrTZNKSzVyPUGyMlcyPyEQvF2= MVnTRW5ITVJ?
DK-MG NWfsbXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D2fGlEPTB;MUKuPVQ5OiEQvF2= NGrnVnlUSU6JRWK=
TCCSUP MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPuTWM2OD1zMz6xNlg1KM7:TR?= MVLTRW5ITVJ?
SCC-15 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF|LkK2OVEh|ryP NUGx[mgzW0GQR1XS
NOS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K0XWlEPTB;MUOuNlg6OyEQvF2= NHXkU|lUSU6JRWK=
RH-1 NX\ubmFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrHTWM2OD1zMz6zNFM4KM7:TR?= NFHBSJFUSU6JRWK=
SK-MEL-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX31S|N3UUN3ME2xN{4{PzJ6IN88US=> NXf0flZvW0GQR1XS
NB5 NVzOO|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;CSWlEPTB;MUOuOFA3PyEQvF2= NUfFUGZKW0GQR1XS
SNU-387 NFy0bphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKxWHlZUUN3ME2xN{42ODd{IN88US=> NGDiVJJUSU6JRWK=
CAL-120 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF|Lk[3NVgh|ryP M1zxRXNCVkeHUh?=
Mo-T NWHrfXExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKxWWRKSzVyPUGzMlcxPyEQvF2= MlrnV2FPT0WU
LNCaP-Clone-FGC NYTWOphmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPafHh{UUN3ME2xN{44QTl{IN88US=> NX25OXV3W0GQR1XS
CAN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ixPGlEPTB;MUSuNFI5QCEQvF2= M2G1OHNCVkeHUh?=
SK-MEL-30 M4XYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7OSmVNUUN3ME2xOE4xPjNizszN NETqPXVUSU6JRWK=
COLO-678 NH24dVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW2bVBWUUN3ME2xOE4xQDJ{IN88US=> MnPnV2FPT0WU
SCC-9 NUHFdJQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:xOotKSzVyPUG0MlExOjFizszN MmHRV2FPT0WU
KINGS-1 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO2TWM2OD1zND6xOFAzKM7:TR?= MYfTRW5ITVJ?
SL-513 NVXSV3FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P0OmlEPTB;MUSuNVg4KM7:TR?= NEfjcYRUSU6JRWK=
HLE M3H0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne5TWM2OD1zND6zPFUzKM7:TR?= NIT0[lhUSU6JRWK=
SW1573 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqzTWM2OD1zND60OFM2KM7:TR?= MX3TRW5ITVJ?
KYSE-140 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfmToprUUN3ME2xOE43OzJ5IN88US=> M1XmOnNCVkeHUh?=
SK-PN-DW NFLySlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\UTWM2OD1zND64NFAyKM7:TR?= M1\vO3NCVkeHUh?=
A253 Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF3LkC2NlUh|ryP MoX6V2FPT0WU
CAL-12T NIn5RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\PcWlEPTB;MUWuOFY3OiEQvF2= Mo[1V2FPT0WU
COLO-679 NWDOc5FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvhTWM2OD1zNT63Olg{KM7:TR?= NH60U2JUSU6JRWK=
UACC-257 NIHJNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF4LkGyNFEh|ryP M{\kSHNCVkeHUh?=
U-87-MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LxTWlEPTB;MU[uN|UzOyEQvF2= Mlz4V2FPT0WU
HCC1806 NVXsbZhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPHTWM2OD1zNj63NFcyKM7:TR?= MU\TRW5ITVJ?
NCI-H2170 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\kTWM2OD1zNz6yOFQ5KM7:TR?= NX\Db2E6W0GQR1XS
AGS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfhTWM2OD1zNz6zPFA5KM7:TR?= NWLweYtbW0GQR1XS
MEL-HO M2nueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF5Lke1NFMh|ryP MUHTRW5ITVJ?
SW48 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF5Lke3NVYh|ryP MWfTRW5ITVJ?
HuP-T4 NGWybZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\GTWM2OD1zOD6wNlA3KM7:TR?= MUHTRW5ITVJ?
NCI-H720 NHXuc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF6LkG0NFIh|ryP NF20NlJUSU6JRWK=
RCC10RGB NHnlepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzCTWM2OD1zOD6xOlk4KM7:TR?= MYTTRW5ITVJ?
HD-MY-Z MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInYdm5KSzVyPUG4MlIzPTRizszN MojxV2FPT0WU
A427 NUjpeG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;uRZVKSzVyPUG4MlUxQTRizszN NX;KV49jW0GQR1XS
HCC2998 M2DPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF6Lk[wOVEh|ryP M2rMSnNCVkeHUh?=
EPLC-272H MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjuc|dKSzVyPUG5MlA1OzRizszN M{fqfnNCVkeHUh?=
C32 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvYW2pWUUN3ME2xPU4xPDVizszN NIL1UlhUSU6JRWK=
UMC-11 M1j0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELmV4pKSzVyPUG5MlIyOjNizszN NYfuZZRoW0GQR1XS
CaR-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF7Lk[4NFQh|ryP M4\kXnNCVkeHUh?=
KYSE-410 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyxc2x1UUN3ME2xPU46OTN7IN88US=> NYLvdVh7W0GQR1XS
HuCCT1 M1OxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\TWpE5UUN3ME2yNE43Ojl2IN88US=> NV\l[FNDW0GQR1XS
LB996-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJyLkexOlgh|ryP MVPTRW5ITVJ?
KYSE-70 NVjaXVBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Hne2lEPTB;MkCuPFA2QSEQvF2= NUnEe3hlW0GQR1XS
CAL-72 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvxU3JDUUN3ME2yNE46OTVizszN MmjwV2FPT0WU
Capan-2 NFzhR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq3TWM2OD1{MT6wOFE{KM7:TR?= M3OzO3NCVkeHUh?=
PANC-08-13 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJbmlEPTB;MkGuNlUyPSEQvF2= MkjZV2FPT0WU
SBC-1 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfWUnBKSzVyPUKxMlMxQDFizszN MlHnV2FPT0WU
MFM-223 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjTSJFmUUN3ME2yNU4{OzR{IN88US=> NYf0bndmW0GQR1XS
BB49-HNC NWm4TIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnRTWM2OD1{MT61O|E3KM7:TR?= NIL3eodUSU6JRWK=
SH-4 M1i1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nPcmlEPTB;MkGuOlYyQCEQvF2= M1XFVXNCVkeHUh?=
HuO9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[5ZmlEPTB;MkGuPVgzPSEQvF2= Mn\SV2FPT0WU
AM-38 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXhTWM2OD1{Mj6wOFg2KM7:TR?= NU\lUZp[W0GQR1XS
A431 NYLLb4lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LEWmlEPTB;MkOuNlEyQSEQvF2= MoDjV2FPT0WU
YAPC NGnrUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHPW4xiUUN3ME2yN{4zPjVzIN88US=> M4nNWnNCVkeHUh?=
LU-139 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ|LkS4NFkh|ryP MnHYV2FPT0WU
HEC-1 M{L3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ|LkS5N|ch|ryP NU\LT4tOW0GQR1XS
SCC-25 M4HmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H2cmlEPTB;MkSuN|AxPiEQvF2= NI\TO4NUSU6JRWK=
HT-29 M2\x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn73TWM2OD1{ND6zPFI{KM7:TR?= MmXLV2FPT0WU
PC-14 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjlTWczUUN3ME2yOE43PTdzIN88US=> M13N[HNCVkeHUh?=
Calu-6 NYTtfXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHhZlRqUUN3ME2yOU42ODdzIN88US=> NVjyZnVtW0GQR1XS
SJRH30 M{nacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfrTWM2OD1{NT62OFk3KM7:TR?= M{j1dHNCVkeHUh?=
ChaGo-K-1 M3Hicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fSfGlEPTB;Mk[uNVYzQSEQvF2= M1TqS3NCVkeHUh?=
IA-LM NV7tTpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3ITWM2OD1{Nj6zOlQ2KM7:TR?= MUDTRW5ITVJ?
GP5d MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[5ZXNEUUN3ME2yOk41PDlzIN88US=> NEKwUppUSU6JRWK=
NCI-H2291 NV3G[GNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\MNmlEPTB;Mk[uOlU1OSEQvF2= NVr3[IRyW0GQR1XS
BALL-1 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJTWM2OD1{Nj65N|k4KM7:TR?= MVLTRW5ITVJ?
HCC1954 NHXGdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ4Lkm4NFgh|ryP NUf5cYNuW0GQR1XS
NCI-H2452 NHvITnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXjTWM2OD1{Nz60NVY{KM7:TR?= NIC5W4NUSU6JRWK=
LU-99A NIDOdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr4cJdTUUN3ME2yO{42PTh{IN88US=> MkXaV2FPT0WU
NTERA-S-cl-D1 NGHLe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XHZmlEPTB;MkeuO|I6QSEQvF2= NHTp[HhUSU6JRWK=
PANC-10-05 NFu0eVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV35NZpmUUN3ME2yO{44Pzd3IN88US=> MWPTRW5ITVJ?
NCI-H2405 NWPCbXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ5LkmzPFch|ryP MUPTRW5ITVJ?
MDA-MB-415 MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LsfmlEPTB;MkiuOFE{PyEQvF2= MXfTRW5ITVJ?
NCI-H2342 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q4W2lEPTB;MkiuOVI5OSEQvF2= NXLD[GtzW0GQR1XS
TGBC24TKB M4S2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M335VWlEPTB;MkiuO|EyPyEQvF2= MV;TRW5ITVJ?
LU-134-A NE[xTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC0UnJKSzVyPUK4MlkzPjFizszN MUjTRW5ITVJ?
SCC-4 NVXhbJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne3TWM2OD1|MT6wOFk1KM7:TR?= MWDTRW5ITVJ?
Saos-2 M{\6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNzLkmzNFYh|ryP MYLTRW5ITVJ?
RERF-LC-MS NHvaV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzZTWM2OD1|Mj64NlMyKM7:TR?= NVjPV5JFW0GQR1XS
M14 NGjwVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;BZYV1UUN3ME2zNk46PzZ2IN88US=> NV7ocWw2W0GQR1XS
HPAF-II NFzZSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrCfVBKSzVyPUOzMlUxOTFizszN M1nHZnNCVkeHUh?=
NCI-H1755 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK0VYZKSzVyPUO0MlM{ODVizszN NVT3cYM3W0GQR1XS
D-392MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN3Lki2O|Qh|ryP MUHTRW5ITVJ?
A704 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTN4LkC0Nlch|ryP Mln3V2FPT0WU
CP50-MEL-B M{TC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLrT2JMUUN3ME2zOk4yQTFzIN88US=> M33lTXNCVkeHUh?=
EW-18 NFP5WnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN4LkS1NkDPxE1? NGDGbI5USU6JRWK=
WM-115 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPITWM2OD1|Nj64NFk6KM7:TR?= MV7TRW5ITVJ?
LU-65 NFz2bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTN5LkG0NVch|ryP NV;nW|N6W0GQR1XS
NCI-H1563 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vCTGlEPTB;M{euNlQ5PCEQvF2= NW\nSoJSW0GQR1XS
DBTRG-05MG MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYiwe3IxUUN3ME2zPE4xPjlzIN88US=> M1zT[XNCVkeHUh?=
NCI-H630 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\MWHhKSzVyPUO4MlQ4OTRizszN M1rzT3NCVkeHUh?=
NCI-H1155 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPzbJRlUUN3ME2zPU4zPDJizszN NV\JSXpLW0GQR1XS
OVACR-3 NWDm[nR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T3V2lEPTB;M{muPVE6PSEQvF2= MkTIV2FPT0WU
OAW-42 M{\HO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnRVoJKSzVyPUSwMlQzPThizszN M1L0WXNCVkeHUh?=
JVM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfNTWM2OD12MT6yOFE2KM7:TR?= M4TGbXNCVkeHUh?=
C3A NY\GUWxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HTeGlEPTB;NEGuN|Q1PyEQvF2= NIrjeXpUSU6JRWK=
HT55 NVzCdlZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrYTWM2OD12Mj6yPFQyKM7:TR?= NFPveWRUSU6JRWK=
OVCAR-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTR{LkK5O|Qh|ryP NEPJNHFUSU6JRWK=
MEG-01 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;wbXhKSzVyPUSyMlQ3OTZizszN M33aS3NCVkeHUh?=
NCI-H82 M3rhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvSRWhKSzVyPUSzMlk5QTJizszN NYfWZWQ5W0GQR1XS
JEG-3 MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDjTWM2OD12ND65OFch|ryP M1vlPXNCVkeHUh?=
BPH-1 NXraOHRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3BTWM2OD12Nj6zPVk5KM7:TR?= NX7NWXhpW0GQR1XS
MPP-89 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\aTWM2OD12Nz6yPFk5KM7:TR?= NELk[JFUSU6JRWK=
ALL-PO NHjnPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXSTWM2OD12Nz60NVg5KM7:TR?= Ml\5V2FPT0WU
HT NX;oZpp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR5LkS5NkDPxE1? MV;TRW5ITVJ?
NCI-H2347 NHnodYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLLW21KSzVyPUS4MlA4OTVizszN NXnJW2FxW0GQR1XS
A2780 NXezW3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTxc4pKSzVyPUS5MlQzOjhizszN NHvJNXVUSU6JRWK=
KARPAS-299 NUj5OWN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR7LkWxNVkh|ryP NIq2d3RUSU6JRWK=
NCI-H1651 NF2wNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi5TWM2OD12OT64PFIyKM7:TR?= NWjr[HptW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID